معرفی
Stephen Hyde is a Professor of Molecular Therapy at the Radcliffe Department of Medicine, University of Oxford, and Co-Director of the Gill and Hyde Group: Gene Medicine Group. His research focuses on developing gene therapy technologies for respiratory diseases, particularly cystic fibrosis. He pioneered the use of gene transfer to correct cystic fibrosis defects in transgenic mice, leading to multiple clinical trials, including a phase IIb study showing improved lung function in patients.
Hyde is a founding Principal Investigator of the UK Cystic Fibrosis Gene Therapy Consortium, a collaborative initiative involving Oxford, Edinburgh, and Imperial College London. His expertise includes viral/non-viral vector design, aerosol delivery systems, and GMP-compliant production. He advises UK health authorities on gene therapy safety and edits journals like Journal of Gene Medicine and Nature Scientific Reports.
Current Research: CpG-free non-viral formulations, lentiviral vector engineering, and CRISPR/Cas9 applications. Recent work includes a first-in-human lentiviral trial and studies on SARS-CoV-2 immune responses.
Key Collaborations: Department of Health’s Gene Therapy Advisory Committee, Committee on the Safety of Medicines.
